Centre of Excellence
King’s Health Partners is one of only two centres in the UK to receive the status of National Parkinson Foundation Centre of Excellence for the treatment and research of Parkinson’s disease.Read more
At the National Parkinson Foundation, they make life better for people with Parkinson’s through expert care and research. Everything they do helps people actively enjoy life with their friends, families, children and grandchildren until there is a tomorrow without Parkinson’s.
King’s Health Partners Academic Health Sciences Centre (AHSC) is a pioneering collaboration between King’s College London, and Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts. We are one of only six AHSCs in England and our partnership brings together an unrivalled range and depth of clinical and research expertise, spanning both physical and mental health. Our combined strengths will drive improvements in care for patients, allowing them to benefit from breakthroughs in medical science and receive leading edge treatment at the earliest possible opportunity.
The Institute of Psychiatry, Psychology and Neuroscience is a research institution dedicated to discovering what causes mental illness and diseases of the brain. In addition, its aim is to help identify new treatments for them and ways to prevent them in the first place.
King’s College London is a public research university located in London, United Kingdom, and a founding college and member institution of the federal University of London.
CRISP is the expert patient group formed to promote PPI (public and patient involvement), which advises EUROPAR on research plans and projects. The group is a member of the INVOLVE, a national advisory group funded by the National institute for Health Research (NIHR). INVOLVE was established to promote Patient and Public Involvement in research, in order to improve the way that research is prioritised, commissioned, undertaken, communicated and used.
One of 15 local branches delivering research in the NHS across all therapy areas. The NIHR Clinical Research Network: South London helps to increase the opportunities for patients to take part in clinical research, ensures that studies are carried out efficiently, and supports the Government’s Strategy for UK Life Sciences by improving the environment for commercial contract clinical research in the NHS throughout the South London area.
We are passionate about the contribution that clinical research can make to patient care, and work collaboratively to translate that passion into the effective delivery of studies in the locality. We make sure that clinical research occupies the place it deserves to in the day-to-day work of the NHS across the South London area. This includes Trusts, primary care organisations and any other qualified providers of NHS services.
Every hour, someone in the UK is told they have Parkinson’s. Because we’re here, no one has to face Parkinson’s alone. We bring people with Parkinson’s, their carers and families together via our network of local groups, our website and free confidential helpline. Specialist nurses, our supporters and staff provide information and training on every aspect of Parkinson’s.
As the UK’s Parkinson’s support and research charity we’re leading the work to find a cure, and we’re closer than ever. We also campaign to change attitudes and demand better services. Our work is totally dependent on donations. Help us to find a cure and improve life for everyone affected by Parkinson’s.
Britannia Pharmaceuticals Limited is a UK based pharmaceutical company specialising in niche innovative products for chronic and serious medical conditions, in particular the treatment of patients with Parkinson’s disease. The need for apomorphine as a treatment option for Parkinson’s disease has led to the development of APO-go and other associated brands around the globe, which are available in many countries through our Distribution or Licensing Partners.
Global Kinetics Corporation is committed to improving the lives of those with Parkinson’s disease and other movement disorders, with advanced medical technologies.
Its lead product, the Parkinson’s KinetiGraph™ (PKG™), has been developed by neurologists at the world-renowned Florey Institute of Neuroscience in Melbourne, Australia. The PKG™ enables the precise monitoring, quantification and reporting of movement patterns of neurological diseases including bradykinesia, dyskinesia, tremor and immobility.
UCB is a patient-centric biopharmaceutical company dedicated to the research, development and commercialisation of innovative medicines with a focus on the fields of central nervous system and immunology disorders.
Lundbeck are a leading pharmaceutical company specialising in central nervous system (CNS) disorders. This strategic focus has allowed us to establish strong links with academics, clinicians and organisations with interests in CNS disorders, such as depression and anxiety, bipolar I disorder, schizophrenia, alcohol dependence, Alzheimer’s and Parkinson’s disease.
Research has been our foundation for more than 50 years and we are known worldwide for our pioneering work.
We reinvest around 20% of our revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from CNS disorders. Lundbeck’s mission is to improve the quality of life for people suffering from psychiatric and neurological diseases.
At Medtronic, we’re committed to Innovating for life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. To do that, we’re thinking beyond products and beyond the status quo – to continually find more ways to help people live better, longer.
Merz, the company behind XEOMIN® (incobotulinumtoxinA), are an independent pharmaceutical company with a passion for research and innovation, dedicated to creating products that will make a difference to peoples’ lives since 1908.
With our Vision of becoming the world’s most Admired, Trusted and Innovative company in the field of botulinum neurotoxin, our substantial investment in research and development, (we spend a fifth of our sales on R&D), is always aimed at improving the lives of patients and offering healthcare professional improved options to manage spasticity and dystonia.
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world’s pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and inflammatory conditions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting-edge treatments to meet the most pressing needs of healthcare professionals and patients.